GlaxoSmithKline PLC Director/PDMR Shareholding (8051Z)
15 Gennaio 2020 - 8:00AM
UK Regulatory
TIDMGSK
RNS Number : 8051Z
GlaxoSmithKline PLC
14 January 2020
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Ms E Walmsley
==== ====================================== ====================================================
b) Position/status Chief Executive Officer
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 9 January 2020
on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP17.9020 195
=========================================== ========================== ======================
GBP17.9020 195
========================== ======================
GBP17.9020 684
========================== ======================
GBP17.9020 680
========================== ======================
d) Aggregated information 1,754
====
Aggregated volume GBP17.9020
Price
=========================================== ====================================================
e) Date of the transaction 2020-01-13
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr R Connor
==== ====================================== ====================================================
b) Position/status President, Global Vaccines
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 9 January 2020
on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP17.9020 101
=========================================== ========================== ======================
GBP17.9020 101
========================== ======================
GBP17.9020 144
========================== ======================
GBP17.9020 178
========================== ======================
d) Aggregated information 524
====
Aggregated volume GBP17.9020
Price
=========================================== ====================================================
e) Date of the transaction 2020-01-13
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr N Hirons
==== ====================================== ====================================================
b) Position/status SVP, Global Ethics & Compliance
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 9 January 2020
on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP17.9020 64
=========================================== ========================== ======================
GBP17.9020 64
========================== ======================
GBP17.9020 75
========================== ======================
GBP17.9020 74
========================== ======================
d) Aggregated information 277
====
Aggregated volume GBP17.9020
Price
=========================================== ====================================================
e) Date of the transaction 2020-01-13
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr L Miels
==== ====================================== ====================================================
b) Position/status President, Global Pharmaceuticals
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 9 January 2020
on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP17.9020 137
=========================================== ========================== ======================
GBP17.9020 190
========================== ======================
d) Aggregated information 327
====
Aggregated volume GBP17.9020
Price
=========================================== ====================================================
e) Date of the transaction 2020-01-13
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr D Redfern
==== ====================================== ====================================================
b) Position/status Chief Strategy Officer
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 9 January 2020
on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP17.9020 80
=========================================== ========================== ======================
GBP17.9020 80
========================== ======================
GBP17.9020 140
========================== ======================
GBP17.9020 168
========================== ======================
d) Aggregated information 468
====
Aggregated volume GBP17.9020
Price
=========================================== ====================================================
e) Date of the transaction 2020-01-13
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Mr R Simard
==== ====================================== ======================================================
b) Position/status President, Pharmaceuticals Supply Chain
==== ====================================== ======================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ======================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ======================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ======================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ======================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 9 January 2020
on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
==== ====================================== ======================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== =========================== ======================
GBP17.9020 61
======================================================================= ======================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
==================================================================== =============================
e) Date of the transaction 2020-01-13
==== ====================================== ======================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ======================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr P Thomson
==== ====================================== ====================================================
b) Position/status President, Global Affairs
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 9 January 2020
on Ordinary Shares held in the Company's
Deferred Annual Bonus Plan.
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP17.9020 76
=========================================== ========================== ======================
GBP17.9020 95
========================== ======================
GBP17.9020 98
========================== ======================
d) Aggregated information 269
====
Aggregated volume GBP17.9020
Price
=========================================== ====================================================
e) Date of the transaction 2020-01-13
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =============================================================================================
a) Name Mr B McNamara
==== ======================================== ===================================================
b) Position/status CEO, GSK Consumer Healthcare
==== ======================================== ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================== ===================================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 9 January 2020 on ADSs
held in the Company's Deferred Annual Bonus
Plan.
==== ======================================== ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ---------------------------------------- ====================== =========================
$46.6500 74
--------------------------------------------- ====================== =========================
$46.6500 72
====================== =========================
$46.6500 68
---------------------- -------------------------
d) Aggregated information 214
====
Aggregated volume $46.6500
Price
============================================= ===================================================
e) Date of the transaction 2020-01-13
==== ======================================== ===================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================== ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Dr H Barron
==== ======================================== ====================================================
b) Position/status Chief Scientific Officer and President,
R&D
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================== ====================================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 9 January 2020 on ADSs
held in the Company's Deferred Annual Bonus
Plan.
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ====================== =========================
$46.6500 406
====================== =========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ========================================================
e) Date of the transaction 2020-01-13
==== ======================================== ====================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Mr J Ford
==== ======================================== ====================================================
b) Position/status Senior Vice President and General Counsel
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================== ====================================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 9 January 2020 on ADSs
held in the Company's Deferred Annual Bonus
Plan.
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ====================== =========================
$46.6500 35
====================== =========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ========================================================
e) Date of the transaction 2020-01-13
==== ======================================== ====================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =============================================================================================
a) Name Ms K Terrell
==== ======================================== ===================================================
b) Position/status Chief Digital & Technology Officer
==== ======================================== ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================== ===================================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 9 January 2020 on ADSs
held in the Company's Deferred Annual Bonus
Plan.
==== ======================================== ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ====================== =========================
$46.6500 24
============================================= ====================== =========================
$46.6500 86
====================== =========================
d) Aggregated information 110
====
Aggregated volume $46.6500
Price
============================================= ===================================================
e) Date of the transaction 2020-01-13
==== ======================================== ===================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================== ===================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHVZLFFBFLXBBE
(END) Dow Jones Newswires
January 15, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024
